Watch for Phase 2b interim data expected in December 2026, which will be the first placebo-controlled readout. Positive 52-week open-label results de-risks the program but small sample sizes (n=3 at highest dose) limit conviction. Monitor for any safety signals in larger Phase 2b.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals reported positive 52-week data from the highest dose cohort (Cohort 9) of its Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis, showing 66% (2/3) of patients maintaining clinical remission at 52 weeks after a single dose. Across all cohorts followed to 52 weeks, 64% (9/14) of patients remained in clinical remission. The company also noted no treatment-related serious adverse events or oropharyngeal candidiasis to date. Interim data from the Phase 2b portion are expected in December 2026.
Key Facts
- Cohort 9 (20x8mg dose): 66% (2/3) maintained clinical remission at 52 weeks per SDI
- Across cohorts 5-9: 64% (9/14) maintained clinical remission at 52 weeks after single administration
- Cohort 8b (20x6mg): mean SDI reduction of 3.3 at 36 weeks; mean EoEHSS Stage reduction -0.26 and Grade reduction -0.27 at 36 weeks
- No treatment-related SAEs, oropharyngeal candidiasis, adrenal insufficiency, or glucose derangement reported across all 10 cohorts
- Phase 2b portion (randomized, placebo-controlled) currently recruiting; interim data expected in December 2026
Financial Impact
No financial data reported; clinical-stage biotech with no revenue. Positive efficacy/safety data supports pipeline value.
Risk Factors
- Small sample sizes in highest dose cohorts (n=3 for Cohort 9, n=4 for Cohort 8b) limits statistical reliability
- Open-label design with no comparator; Phase 2b placebo-controlled data will be critical
- Clinical-stage company with no approved products; requires additional financing and regulatory approval
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006307 |
| Document: f6k_093026.htm | 0001171843-26-006307 |
| Document: 0001171843-26-006307-index-headers.html | 0001171843-26-006307 |
| Document: 0001171843-26-006307-index.html | 0001171843-26-006307 |
| Document: 0001171843-26-006307.txt | 0001171843-26-006307 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.87 (−9.49%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.87 (+1.48%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.87 (−7.91%) |
Sep 30, 2026 26d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.87 (−24.51%) |
Sep 30, 2026 26d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.87 (−24.51%) |
Aug 25, 2026 8w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.87 (+7.41%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.87 (+3.00%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.87 (+6.02%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.87 (+5.37%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.87 (+3.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers